PCT Reassessed

Procalcitonin serves as a valuable biomarker for guiding antibiotic discontinuation in critically ill patients, though its role in the initial decision to start therapy remains limited. As an acute phase reactant, procalcitonin exhibits favorable kinetics, rising and falling rapidly in response to bacterial infections. Recent research, including the ADAPT sepsis trial, demonstrates that using procalcitonin-guided algorithms can reduce the duration of antibiotic therapy without compromising patient mortality. Despite these findings, clinical reliance on this biomarker requires caution due to potential false positives from conditions like SARS-CoV-2 and the necessity of consistent protocol adherence. Ultimately, effective antimicrobial stewardship—anchored by evidence-based shorter treatment durations—often proves more impactful than biomarker testing alone. Infectious disease specialist Dr. Simran Gupta emphasizes that while procalcitonin offers a useful tool for refining treatment, it functions best as an adjunct to comprehensive clinical evaluation rather than a definitive diagnostic solution.